Johnson & Johnson, AstraZeneca researching vaccine modification to address rare blood clot risk

Johnson & Johnson (J&J) and AstraZeneca are researching vaccine modification to address the rare blood clot risk associated with the companies’ coronavirus vaccine. People familiar with the situation told the Wall Street Journal the two…